Mozobil
plerixafor
Table of contents
Overview
Mozobil is a medicine used to mobilise blood stem cells from a patient’s bone marrow so that they can be collected and used later for transplantation in the same patient.
Mozobil is used together with the hormone granulocyte-colony stimulating factor (G-CSF) and is only for patients in whom collection of stem cells is difficult.
The patients who are given Mozobil are:
- adults with lymphoma or multiple myeloma (types of blood cancer);
- children from 1 year of age who have lymphoma or solid tumours.
Mozobil contains the active substance plerixafor.
-
List item
Mozobil : EPAR - Medicine overview (PDF/84.48 KB)
First published: 20/08/2009
Last updated: 02/09/2019
EMA/254533/2019 -
-
List item
Mozobil : EPAR - Risk-management-plan summary (PDF/70.63 KB)
First published: 02/09/2019
Authorisation details
Product details | |
---|---|
Name |
Mozobil
|
Agency product number |
EMEA/H/C/001030
|
Active substance |
Plerixafor
|
International non-proprietary name (INN) or common name |
plerixafor
|
Therapeutic area (MeSH) |
|
Anatomical therapeutic chemical (ATC) code |
L03AX16
|
Publication details | |
---|---|
Marketing-authorisation holder |
Sanofi B.V.
|
Revision |
22
|
Date of issue of marketing authorisation valid throughout the European Union |
30/07/2009
|
Contact address |
Paasheuvelweg 25 |
Product information
13/04/2023 Mozobil - EMEA/H/C/001030 - IAIN/0049
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Immunostimulants
Therapeutic indication
Mozobil is indicated in combination with granulocyte-colony-stimulating factor to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma whose cells mobilise poorly.